With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.694499-26-8,4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline,as a common compound, the synthetic route is as follows.
A mixture of 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid (1.95 g, 5.5 mmol), 4-(4- Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylamine (1.5 g, 5.49 mmol) and triethylamine (6.42 mL, 46.2 mMol) in dry DMF (50 mL) is heated under an argon atmosphere at 500C. A solution of propylphosphonic anhydride (5.4 mL, 8.2 mmol) 50% inDMF is then added. After 2 h, the reaction mixture is poured onto an aqueous solution of NaHCO3 and stirred at 00C for 1h. The suspension is then filtered (hyflo) and the solid residue is dissolved in CH2CI2 – MeOH (5:1). The solvent is evaporated off under reduced pressure to afford a crude product which is purified by reversed phase MPLC (Bchi system), yielding, after neutralisation with saturated aqueous NaHCO3, the title compound as a orange solid., 694499-26-8
The synthetic route of 694499-26-8 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/31265; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics